Xenikos xenikos.com


Public list: Pharma Startups (4733) Cancer Therapeutics (1136)

Xenikos is developing new immunotherapies based on conjugate Antibodies are based and the health and quality of life of patients to improve. This therapeutic approach contributes to this at, the patient's own immune system in severe immune disorders or Rejection reactions after transplants efficient and fast restore. Xenikos' lead candidate, T-Guard, stands as Second line treatment for steroid-resistant acute Graft-versus-host disease in patients after hematopoietic Stem cell transplantation pri...Show all

Xenikos is developing new immunotherapies based on conjugate Antibodies are based and the health and quality of life of patients to improve. This therapeutic approach contributes to this at, the patient's own immune system in severe immune disorders ...Show all

Company (Alive / Active)

Phone: +31 24 300 01 00

Fax:

Molenveldlaan 168

Nijmegen, 6523 RN
Netherlands

Latest News

See more competitors data Competitors
Total Funding Date of Last Funding
Xenikos $34.7M May 15, 2018

Web Traffic

Rank

Show (-10)

Engagement (PVPU)

Show (+1%)

Domain Authority Score
Show
Page Views Per Million (PVPM)
Show
Reach Per Million
Show

SEO Statistics

Domain Authority Score Show
Page Authority Score Show
No. External Links Show
No. Links Show

Web Traffic Statistics - Growth

Per Week Per Month Per 6 Months Per Year
Rank Login to see details
Page Views Per Million Login to see details
Page Views Per User Login to see details
Reach Per Million Login to see details

Related Xenikos Jobs

jobs by Indeed job
						search

Investors

Investor Investor Type Location Participating Rounds
See all 4 investors
There is no Competitors data available for this company. Please select another tab.

Patents

Title Application Date Patent Date Status
(Patent / Application)